Aktuellt
SENASTE
Redeye is encouraged by yesterday’s news that Lipigon’s phase I trial with Lipisense has been approved by the regulatory authorities. Lipisense, which is an antisense drug, silences the expression of ANGPTL4 in the liver, which should lead to a lowering of blood triglyceride levels. Even though it is a phase I trial mainly centered on security and pharmacokinetics, efficacy will also be measured in the form of blood triglyceride reduction.
LÄS MER
